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Abstract: Asthma is a chronic inflammatory disease of the airways, affecting approximately 300 million people worldwide. Asthma 
results in airway hyperresponsiveness, leading to paroxysmal symptoms of wheeze, cough, shortness of breath, and chest tightness. 
When these symptoms remain uncontrolled, despite treatment with high doses of  inhaled and ingested corticosteroids, asthmatic patients 
are predisposed to greater morbidity and require more health care support. Treating patients with severe asthma can be difficult and often 
poses a challenge to physicians when providing ongoing management. This clinical review aims to discuss the definition, prevalence 
and evaluation of severe asthmatics, and provides a review of the existing pharmacologic and non-pharmacologic treatment options.
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Introduction
Asthma is a complex,1 multi-factorial chronic airway 
disease, of all ages and both sexes. Severe asthma 
represents a heterogeneous group, with data from the 
Severe Asthma Research Program (SARP) describing 
five distinct phenotypes through cluster analysis.1–8 
The  etiology  of  asthma  involves  genetic,  environ-
mental and inflammatory components. The principle 
pathophysiology  of  this  chronic  airway  disease  is 
chronic inflammation of the lower respiratory tract.9 
The prevalence of asthma is increasing worldwide.10 
Data from National Health Interview Surveys from 
Centers for Disease Control and Prevention (CDC) 
showed an increase in prevalence of asthma in the 
United States, from 7.3% in 2001 to 8.2% in 2009.11 
The  Canadian  National  Population  Health  Survey 
showed that the prevalence of asthma in males and 
females .12 years in 1996/97 was 7.2% and in 2005 
was 8.3%.12 Asthma is twice as common in obese 
people as non-obese.13
Definition of severe/refractory asthma
The Canadian Asthma Consensus Guidelines defines 
asthma  as  “a  disease  characterized  by  paroxysmal 
or persistent symptoms of dyspnea, chest tightness, 
wheezing, sputum production and cough, associated 
with variable airflow limitation and airway hyperre-
sponsiveness to endogenous or exogenous stimuli.”14 
The Global Initiative for Asthma (GINA)15 diagnos-
tic criteria similarly are airway hyperresponsiveness 
that leads to recurrent episodes of wheezing, breath-
lessness, chest tightness, and coughing, particularly 
at night or in the early morning along with variable 
airflow obstruction which is often reversible either 
spontaneously or with treatment. Thus, the definition 
of asthma is quite general and relies on clinical and 
physiological parameters. It allows for the capture 
of numerous syndromes able to meet such criteria.16 
In the face of this general definition, defining severe 
asthma becomes even more difficult.
Asthma,  in  clinical  trials  and  clinical  practice, 
is  classified  as  mild,  moderate  and  severe  and  is 
  further sub-categorized as mild-persistent, moderate-
  persistent and severe-persistent based upon   symptoms, 
need for rescue therapy or lung function. However, 
since the Canadian Asthma Consensus   Conference 
in 1996,17 the concept of an asthma continuum was 
adopted.  Asthma  continuum  reflects  a  dynamic 
therapeutic approach that allows drug therapy to be 
adapted to the severity of the underlying illness and 
facilitates adjustment of the intensity of therapy to 
the degree of control achieved. In 1996, it was also 
agreed  upon  that  asthma  “control”  and  “severity” 
should be differentiated.17,18 Severity is defined by the 
minimum medication required to achieve adequate 
asthma control rather than by symptoms or abnormal 
lung function.17,18 Thus, severe asthma is defined as 
well controlled asthma symptoms on high to very high 
doses of inhaled corticosteroids, with or without the 
use of oral corticosteroids; and very severe asthma is 
defined as well or not well controlled asthma symptoms 
despite very high dose of inhaled and ingested corti-
costeroids and with or without requiring additional 
therapies. For this classification, the daily high and 
very high doses of inhaled corticosteroid (approximate 
equivalent doses) are defined as follows: High dose 
is beclomethasone diproprionate, 1000 to 2000 µg; 
fluticasone, 500 to 1000 µg; and budesonide, 800 to 
1600 µg and very high dose is fluticasone, 1000 to 
2000 µg and budesonide, 1600–3200 µg.
The  term  “refractory  asthma”  was  agreed  upon 
at the American Thoracic Society workshop.19 It is 
not meant to describe only patients with “fatal” or 
“near fatal” asthma, but it is meant to encompass the 
asthma  subgroups  previously  described  as  “severe 
asthma,” “steroid-dependent and/or resistant asthma,” 
“difficult  to  control  asthma,”  “poorly  controlled 
asthma,” “brittle asthma,” or “irreversible asthma.”19 
Refractory asthma can be defined as per the American 
Thoracic Society guidelines when one or both major 
criteria and two minor criteria, described as follows, 
are fulfilled. The major criteria are: In order to achieve 
control to a level of mild-moderate persistent asthma: 
(1)  Treatment  with  continuous  or  near  continuous 
($50% of year) oral corticosteroids 2) Requirement 
for treatment with high-dose inhaled corticosteroids. 
The  minor  criteria  are:  (1)  Requirement  for  daily 
treatment  with  a  controller  medication  in  addition 
to inhaled corticosteroids eg, long-acting β-agonist, 
theophylline  or  leukotriene  antagonist  (2)  Asthma 
symptoms requiring short-  acting β-agonist use on a 
daily or near daily basis (3)   Persistent airway obstruc-
tion (FEV1 , 80% predicted; diurnal peak expiratory 
flow (PEF) variability . 20%) (4) One or more urgent 
care visits for asthma per year (5) Three or more oral 
steroid  “bursts”  per  year  (6)  Prompt  deterioration Management of severe asthma
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with #25% reduction in oral or inhaled corticosteroid 
dose (7) Near fatal asthma event in the past. To make 
the diagnosis of refractory asthma, it is necessary that 
other  conditions  have  been  excluded,  exacerbating 
factors treated, and the patient felt to be generally 
adherent. For the purposes of definition of refractory 
asthma, the drug (µg/d) and the dose (puffs/d) are as 
follows: (a) Beclomethasone dipropionate . 1,260 . 
40 puffs (42 µg/inhalation) . 20 puffs (84 µg/inhala-
tion); (b) Budesonide . 1,200 . 6 puffs; (c) Flunisolide 
. 2,000 . 8 puffs; (d) Fluticasone propionate . 880 . 
8 puffs (110 µg), . 4 puffs (220 µg); (e) Triamcinolone 
acetonide . 2,000 . 20 puffs.19
Prevalence of severe/refractory asthma
Definition of severe or refractory asthma is not uni-
form in the literature; hence it is difficult to estimate 
the true disease prevalence. Most asthma is mild to 
moderate and can be controlled by minimal medica-
tion which include inhaled β–agonists and inhaled 
corticosteroids. Only about 5%–10%, likely ,5%,19 
of  total  asthmatic  subjects  have  difficult  disease 
which requires higher doses medication to achieve 
  adequate control or have persistent symptoms, asthma 
  exacerbations and airway obstruction despite higher 
medication  use.16,20  Thus,  these  severe  asthmatic 
groups of subjects have greater morbidity and a dis-
proportionate need for health care support compared 
with the less severe subset.21
evidence-based Management  
of severe/Refractory Asthma:  
Optimal General Management
The  diagnosis  of  asthma  should  be  confirmed,  as 
misdiagnosis of asthma could be as high as 30%.22 
Alternative  diagnoses  such  as  chronic  obstructive 
pulmonary disease, left ventricular failure, localized 
obstruction,  cystic  fibrosis  and/or  vocal  cord 
dysfunction should be ruled out.20 Once the diagnosis 
of asthma is objectively confirmed, utilization of the 
concept of asthma continuum is a key in monitoring 
any  asthma  patient  including  severe/refractory 
asthma.  Goals  of  care  of  severe/refractory  asthma 
are: to prevent chronic and troublesome symptoms, 
to normalize pulmonary function, to maintain normal 
activity levels, to prevent exacerbations, to improve 
health-related quality of life and to provide optimal 
pharmacotherapy with minimal or no adverse effects. 
General treatments must include patient education, 
development of an action plan, smoking cessation, 
and review of medication adherence and symptom 
triggers.
Asthma education
Asthma education with the help of an asthma educator 
or Certified Respiratory Educator23 is very helpful in 
improving patient understanding and participation in 
asthma care. Key components of asthma education, 
as demonstrated with the Canadian experience, are 
individual teaching and group sessions.7 All asthmatics 
should be referred to asthma education centers after 
the physician has initiated asthma education. Basic 
information  with  practical  applications  should  be 
provided, including: manifestations and mechanisms of 
asthma (inflammation vs. bronchoconstriction), inciters 
and  inducers,  environmental  control/prophylaxis, 
goals of asthma treatment, medication use and side-
effects, inhaler use, assessment of severity and control 
of asthma, use of an action plan, use and interpretation 
of  peak  flow  measurements  and  information  on 
available resources. Subjects should be provided with 
skills for self-management and telephone consultations 
or  other  visits  with  the  health  educator  should  be 
offered. Group sessions should include lectures and 
discussions on practical aspects of asthma in relation 
to management; and participation in a support group 
should be offered.7
Asthma action plan
A personalized self-treatment written Asthma Action 
plan guided by symptoms or peak flow meter should 
be developed in collaboration with the educator and 
the  respirologist.19  The  action  plan  should  include 
instructions  regarding  the  maintenance    medication 
schedule,  doses  of  rescue  therapy  for  increased 
symptoms,  and  when  and  how  to  seek  urgent  or 
  emergency care. A personalized action plan should 
give clear guidance to optimal asthma control vis-à-vis 
no/minimal shortness of breath, cough or wheezing, 
no/minimal limitation of physical activities, no night 
time  awakenings  and  less  than  15%  variability  in 
diurnal PEF. For all asthma patients, including those 
with  severe/refractory  asthma,  inhaler  technique 
should be reviewed and instruction included in action 
plan.Pakhale et al
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Smoking
Cigarette smoking is a very common airway irritant 
in many asthmatics and it reduces inhaled corticosteroids 
(ICS)  effectiveness. A  multidisciplinary  approach  to 
smoking  cessation  should  be  used  in  dealing  with 
current smokers.24 Smoke-free legislation passage and 
strict adherence is essential in asthma care.   Introduction 
of the comprehensive smoke-free legislation in Scotland 
recently  demonstrated  that  there  was  a  reduction  in 
the incidence of asthma among people who did not 
have occupational exposure to environmental tobacco 
smoke.25
Adherence
Patient adherence to asthma care should be reviewed 
in  each  clinic  visit.  Significantly  poor  adherence 
(less  than  50%  prescription  refill),  especially  to 
corticosteroid  therapy,  has  been  demonstrated 
in  severe,  difficult-to-control-asthma  subjects. 
Poor  adherence  is  identified  badly  by  physician 
assessment and patient self report, thus, objective, 
surrogate  and  direct  measures  of  adherence 
should be performed as part of a difficult asthma 
assessment  and  are  important  before  prescribing 
expensive  novel  biological  therapies.26  A  multi-
level  intervention  using  a  simple  concordance 
interview  and  a  menu  driven  psycho-educational 
intervention  strategy  was  studied  in  severe, 
difficult-to-control asthmatic subjects.27 The menu 
driven intervention was designed and delivered by 
an experienced respiratory nurse with basic level 
psycho-therapy training. This model encompassed 
the Transtheoretical Model of Change, Motivational 
Interviewing  and  Cognitive  Behavioural  Therapy 
principles,  providing  a  flexible  short  term 
intervention  using  patient’s  individual  reasons 
for non-adherence as a guide to plan intervention 
content.  The  model  used  a  non-confrontational 
technique  which  elicited  self-motivation  and 
provided a process to resolve ambivalence towards 
medication  taking.  This  multi-level  intervention 
technique was shown to be effective in improving 
adherence to asthma treatment. Most importantly, 
this  relatively  simple  menu  driven  intervention 
strategy reduced prescribed daily dose of inhaled 
corticosteroid (ICS), rescue prednisolone courses, 
hospital admissions and reduced maintenance oral 
steroid dose in subjects on maintenance steroids.27
vaccination
Preventive  vaccinations  such  as  yearly  influenza 
vaccines and pneumococcal polysaccharide vaccine 
are important for all asthmatic subjects and especially 
cigarette  smokers.28  A  nested  case–control  study 
demonstrated  that  asthma  is  an  independent  risk 
factor for invasive pneumococcal disease and that the 
risk among persons with asthma was at least double 
that among controls.29
Management of comorbidities
Many comorbid conditions may occur with asthma 
especially gastroesophageal reflux disease (GERD), 
rhinitis/sinusitis, psychological disturbances, chronic 
infections, obstructive sleep apnea (OSA), obesity, 
and allergic bronchopulmonary aspergillosis (ABPA). 
Interaction  of  these  comorbidities  with  asthma 
may be complex. Some of these comorbidities may 
change asthma phenotype,30 they may complicate the 
course of asthma or may act as confounding factors 
in the diagnosis or assessment of asthma control.31 
Social and environmental exposures may result into 
some comorbidities. Effect of these comorbidities on 
asthma may be variable and may alter response to 
asthma treatment. These comorbidities thus, needs to 
be assessed systematically and treated appropriately, 
especially in the presence of severe asthma as the 
prevalence of these comorbidities seems high.31
GeRD
A randomized, placebo-controlled trial demonstrated 
no  role  of  proton-pump  inhibitors  in  severe 
asthmatics without any symptoms of reflux disease.32 
Furthermore,  the  meta-analysis  of  all  randomized 
controlled  trials  with  proton-pump  inhibitors 
and  asthma  demonstrated  statistically  significant 
improvement in the morning peak flow but such low 
magnitude improvement in peak-flow is unlikely to 
have any clinical significance.33 Thus, proton-pump 
inhibitors can not be recommended for empirical use 
in asthmatics.
Obesity and OSA
Reduced response to standard asthma medications, 
including inhaled cortico-steroid and bronchodilators, 
in obesity might lead to severe asthma.34 Reasons for 
this  reduced  response  are  not  known. Weight  loss 
does seem to improve asthma symptoms and peak Management of severe asthma
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flow.35  Obstructive  sleep  apnea  may  be  associated 
with asthma and obesity. The relationship between 
asthma and obesity is not completely understood yet. 
However, OSA is associated with upper and systemic 
airway  inflammation36  and  thus,  could  complicate 
asthma management.
Psychological disturbances
Psychological elements such as anxiety, depression 
and  panic  disorders  are  more  frequent  in  severe 
asthmatics and thus need to be attended promptly.31,37 
Moreover,  psychological  factors  such  as  anxiety 
and depression are associated with poor adherence 
to inhaled asthma treatment and hence need special 
attention.38
Allergic factors and ABPA
Allergic bronchopulmonary aspergillosis may com-
plicate  asthma  control  and  could  lead  to  central 
bronchiectesis.39  Several  allergic  and  non-allergic 
factors should be carefully examined at each clinic 
visit  pertaining  to  home,  social  and  occupational 
environments of severe asthmatic subjects because 
exposure to these factors can worsen asthma symp-
toms.40 Unidentified allergens could be at home or at 
the work place. Allergens at home such as dust mites, 
cats, cockroaches and other domestic pets should be 
reviewed. There is little evidence in the literature that 
shows clinical benefit to using physical and chemical 
practices to reduce dust mite or pet allergens; further 
studies are required.41 Sensitization to molds has been 
identified as a risk factor for severe asthma in a mul-
ticentre  epidemiological  survey  of  30  centers,  and 
therefore should be reviewed.42
Dietary factors such as dietary-salicylates, mono-
sodium glutamate could be potential allergens. Drugs 
such  as  non-steroidal  anti-inflammatory  agents, 
including aspirin, and oral or ophthalmic ß–blockers 
could  be  contributing  to  asthma  trigger  or  sever-
ity. Exposure to allergens at the work place such as 
chemicals, fumes, dust vis-à-vis asthma severity on 
week-days vs. weekends and holidays is important 
in the history. Detailed occupational history to rule 
out occupational asthma is important.20 Allergy test-
ing can be considered to identify triggers and pos-
sibly prepare for immunotherapy. A Cochrane review 
performed  by  Abramson  and  colleagues  showed 
immunotherapy reduces asthma symptoms, need for 
asthma  medication  and  bronchial  hyper-reactivity. 
There is a possibility of developing local and sys-
temic adverse events, including anaphylaxis, when 
undergoing this therapy.43
Optimal pharmacotherapy for severe/
Refractory Asthma
Mainstay  pharmacotherapy  for  severe/refractory 
asthma  is  combination  of  inhaled  corticosteroids 
(ICS) and one or two controller agents such as long 
acting ß-agonists (LABA), leukotriene modifiers or 
oral theophylline.19 Recently, tiotropium bromide was 
demonstrated to be effective as an add-on controller 
therapy to ICS in uncontrolled asthma.44 No studies 
have evaluated the benefits of multiple combinations 
of these alternative controllers. Thus, in the absence 
of data, clinicians should carefully monitor clinical 
parameters to assess the best combination of control-
ler medications.19 If control is obtained and maintained 
for a three month period, the treatment regime can be 
stepped down to establish the lowest effective dose 
that maintains control.8
Use of corticosteroids in severe asthma
ICS have been shown in multiple studies, over four 
decades,  to  have  efficacy  in  reducing  asthmatic 
symptoms, improving quality of life, improving lung 
function,  decreasing  airway  hyperresponsiveness, 
reducing  frequency  and  severity  of  exacerbations 
and reduction in asthma related mortality.15,45 Inhaled 
corticosteroids  have  effective  anti-inflammatory 
effects  in  patients  with  severe  asthma.15,46  It  is 
believed  that  steroids  in  the  airway  suppress  the 
transcription, production and downstream effects of 
inflammatory cytokines. This results in a   reduction 
of chronic inflammation in the airways of   asthmatic 
patients.46,47 ICS primarily act upon the airway mucosa 
but are systemically absorbed via the lung at higher 
doses. They are metabolized mainly by the liver, and 
excreted  via  the  gastrointestinal  and  genitourinary 
tracts.48 Aiming for the lowest dose of ICS to achieve 
the best asthma control is important because, low dose 
ICS (,250 mcg fluticasone per day, or equivalent) 
acts locally on the airway mucosa with minimal side 
effects. At doses .500 mcg/day of fluticasone (or 
equivalent), local side effects become more apparent.45 
These include oropharyngeal candidiasis, dysphonia, 
and cough due to upper airway irritation.45 All ICS Pakhale et al
42  Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2011:5
will further demonstrate systemic side effects with 
escalating  doses.49  These  are  generally  less  severe 
than those observed with the equivalent dose of oral 
steroids.49  Lipworth’s  systematic  review  and  meta 
analysis in 1999 revealed a greater dose-related sys-
temic effect with fluticasone compared to other corti-
costeroids, especially with doses above 0.8 mg/day.49 
The systemic side effects exhibited by absorption of 
ICS via the lung include, easy bruising, adrenal sup-
pression and decreased bone mineral density.15,49
In  severe  persistent  asthma,  patients    experience 
symptoms despite the use of low dose ICS and LABA’s. 
While dose response curves for ICS seem to plateau 
at low to moderate doses, a report from the National 
Asthma Education and Prevention   Program suggests 
that in severe cases, twice daily therapy with high dose 
ICS should be used, in addition to other measures of 
control 50,51 It is not entirely clear which optimal dose 
and  combination  of  controller  medications  should 
be employed in severe/refractory asthma to produce the 
maximum clinical benefit.19 ICS, however, represent 
the cornerstone of maintenance therapy for patients 
with asthma.45 Evidence indicates that over 90% of 
benefit from ICS is achieved at low doses (,250 mcg 
fluticasone per day, or equivalent).52,53 Before increas-
ing the dose of ICS to moderate or high levels, add-on 
therapy with LABA’s or LRTA’s are recommended.45 
However, if patients continue to be refractory to this 
therapy, there is evidence that increasing the dose of 
ICS may be beneficial.54 In fact, in patients with severe 
asthma who are already dependent on oral corticoster-
oids, therapy with high dose ICS (.500 mcg flutica-
sone per day or equivalent) can be beneficial for lung 
function and quality of life.55 Further, increasing the 
ICS dose may allow for tapering and eventual removal 
of the oral corticosteroid.55
Oral steroid therapy is indicated in the management 
of  patients  with  severe  refractory  asthma,  not 
responsive  to  step-wise  conventional  treatments.45 
The  lowest  dose  possible  should  be  maintained.19 
Given the side effect profile of long term oral steroid 
usage, osteoporosis prevention should be addressed,45 
when prescribing oral steroid therapy.
Steroid  resistance  or  insensitivity  should  be 
assessed  if  asthma  remains  uncontrolled  despite 
high ICS dose and pre-bronchodilator FEV1 , 70% 
predicted with persistence of bronchial reversibility.19 
A one to two week trial of an oral steroid in divided 
doses (40 mg/day or double the dose if already on oral 
steroid) is recommended, while observing the effect on 
morning pre-bronchodilator FEV1.19 If the FEV1 fails to 
increase by 15% (and 200 ml), the patient is considered 
steroid resistant.19 This trial also gives an opportunity 
to assess and address the issue of adherence to therapy. 
Subjects  with  severe/refractory  asthma  who  remain 
symptomatic despite optimal application of conven-
tional therapy and management of comorbidities, alter-
native therapies given below could be considered.
Steroid sparing agents
Due to the side-effect profile of systemic steroids, 
several  alternative  options  have  been  evaluated  in 
treating severe/refractory asthma. Cochrane review of 
randomized controlled trial determined that there was 
insufficient evidence to support the use of   azathioprine, 
chloroquin, cyclosporine, gold or methotrexate in the 
treatment of chronic asthma as a steroid sparing-agent. 
For most of these agents the side-effect profile is not 
preferable.56–60 Add-on therapies such as macrolides, 
anti-IgE  therapy    (omalizumab),  tumor  necrosis 
factor-α inhibitors, cytokine receptor antagonists and 
bronchial thermoplasty are discussed below.
Macrolides
Macrolide antibiotics have shown immunomodulatory 
effects  in  neutrophilic  lung  diseases  such  as 
panbronchiolitis in East Asians and cystic fibrosis.61–65 
More  recently,  clarithromycin  was  demonstrated 
to  modulate  IL-8  and  neutrophil  accumulation  in 
refractory asthmatics in a randomized trial. In addition, 
treatment  with  oral  clarithromycin  in  a  randomized 
placebo controlled trial has shown to reduce severity 
of  bronchial  hyperresponsiveness  in  asthmatics.66 
A  double-blinded,  randomized  controlled  trial  of 
clarithromycin or placebo added to low dose fluticosone 
in sub-optimally controlled asthmatics, did not show 
any  improvement  in  control  of  symptoms.67  Thus, 
macrolide  therapy  may  be  an  important  additional 
therapy that could be used to reduce noneosinophilic 
airway  inflammation,  particularly  neutrophilic 
inflammation, though clinical outcome benefit is still 
unclear.68
Antifungal therapy
Sensitization to molds has been shown to be a risk 
factor  for  severe  asthma.42  A  randomized  placebo Management of severe asthma
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controlled trial by Denning and colleagues on severe 
asthmatics with fungal sensitization demonstrated by 
skin prick or specific IgE testing showed treatment 
with oral itraconazole (200 mg twice a day) over a 
32 week period increased asthma related quality of 
life. Subjects with ABPA were excluded from this 
trial.69 The mechanism by which antifungal therapy 
improves patient symptoms is not clearly understood. 
At this time, further research is required in patient 
selection and optimal duration of therapy.70
Anti-Ige therapy (Omalizumab)
Immunoglobulin  E  (IgE)  plays  a  pivotal  role  in 
the  molecular  pathway  responsible  for  the  allergic 
response.71 Previous literature has demonstrated that 
patients with asthma have elevated circulating IgE 
levels, which implies an allergic basis to the disease.72 
In allergic asthma, aeroallergens sensitize and trigger 
an  immune  based  allergic  inflammatory  response, 
mediated  via  IgE.73  Given  this,  significant  interest 
has been generated in targeting this molecule as a 
treatment in patients with allergic asthma who are not 
well controlled on conventional therapies.
Omalizumab is a humanized recombinant mono-
clonal anti-IgE antibody73,74 This antibody binds to 
free  circulating  IgE  molecules  in  the  bloodstream, 
thereby preventing IgE from binding to mast cells, 
basophils and other immune cells.74,75 Without sur-
face bound IgE, immune cells cannot be activated by 
allergens. This results in a slowing of the allergic and 
inflammatory cascade.76 Omalizumab also reduces the 
overall density of immune cell surface IgE receptors, 
creating less potential for immune cell stimulation.76,77 
Further, studies indicate that Omalizumab does not 
bind to IgE receptors itself, and therefore cannot initi-
ate an allergic and inflammatory response.75
Omalizumab is administered subcutaneously and 
has a mean half-life of 26 days.76,78 Therefore, monthly 
administration  of  the  drug  is  usually  sufficient. 
Treatment dose is determined in accordance with body 
weight and serum total IgE levels prior to treatment.76 
Dosage adjustments during the course of therapy are 
required should there be significant changes in body 
weight.78 Drug metabolism occurs primarily via the 
hepatic system, while the IgE molecules are degraded 
by  the  reticuloendothelial  system.  There  are  no 
controlled studies to evaluate the effect of Omalizumab 
in pregnant women, but animal studies have confirmed 
no teratogenicity.64 Omalizumab is recommended for 
use in pregnant women only if clearly required.78
The most common side effects associated with sub-
cutaneous injection of Omalizumab include headache, 
local injection site reaction and upper respiratory tract 
infection.78 In post marketing surveillance data, anaphy-
lactic reactions have also been reported as a side effect, 
with a frequency of 0.2%.79   Anaphylaxis in this popula-
tion manifested as symptoms of wheezing, shortness of 
breath, chest tightness, angioedema of the tongue and 
throat, hypotension, syncope, and hives.80 While rela-
tively uncommon, anaphylactic reactions were found to 
occur after the administration of the first dose, and up 
to one year after initiation of Omalizumab80 Other side 
effects,  including  malignant  neoplasms,  thrombocy-
topenia and parasitic infections, have also been evalu-
ated.79 Thus far, none of these side effects have shown 
direct  statistical  correlation  with  administration  of 
Omalizumab.79 Additional studies are currently under-
way to assess long term safety data for Omalizumab.79
Several studies evaluating Omalizumab have dem-
onstrated a clinical effect on markers of airway inflam-
mation,  exacerbation  frequency,  emergency  room 
visits, asthma symptom severity, inhaled corticoster-
oid use, and quality of life in patients with moderate 
to severe asthma.73,81–86 A placebo controlled study by 
Djukanović and colleagues in 2004 demonstrated that 
treatment with Omalizumab for 16 weeks reduced 
serum IgE levels, IgE, cells in the airway mucosa, 
and sputum eosinophil counts in patients with mild 
to moderate asthma.81 Interestingly, this study did not 
demonstrate  significant  improvements  in  hyperre-
sponsiveness to methacholine.81 A more recent study 
in 2010 involving patients with severe asthma again 
demonstrated  an  effect  of  Omalizumab  on  airway 
inflammation.82 This study demonstrated a reduction 
in airway expression of endothelin-1, an important 
mediator in airway inflammation and remodeling.82
In addition to inflammatory markers,   Omalizumab 
has  also  demonstrated  efficacy  in  reducing  the 
frequency  of  asthma  exacerbations  and  inhaled 
  corticosteroid requirements. This data comes from sev-
eral studies, including two key randomized controlled 
trials.83,84 Both trials demonstrated a significant reduc-
tion in exacerbations and use of inhaled corticosteroids 
compared with placebo in moderate to severe, and 
severe asthmatics. In the INNOVATE study, a ran-
domized  control  trial  by  Humbert  and  colleagues, Pakhale et al
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Omalizumab was shown to reduce emergency room 
  visits and exacerbations, when added to high dose ICS 
and LABA therapy. This study also assessed severe 
asthmatics.87 Asthma related quality of life has also 
been studied as an endpoint in patients treated with 
Omalizumab.85,86 Chipps and colleagues completed a 
pooled analysis of six controlled trials which revealed 
a  significant  clinically  meaningful  improvement  in 
quality of life after treatment with Omalizumab.85 This 
effect was seen in patients with severe asthma.
Given the clinical benefits of Omalizumab in patients 
with moderate to severe allergic asthma, cost effec-
tiveness has also been evaluated. The baseline cost of 
Omalizumab is high, at $10,000 to $12,000 USD per 
year for patients receiving the minimum dose every 4 
weeks.88 Therefore, careful patient selection is para-
mount. A retrospective economic analysis published in 
2004 calculated a cost of $523 per day to achieve one 
successful symptom controlled day.88,89 From this cost 
perspective, they concluded that Omalizumab should 
be considered in severe asthmatics on maximal therapy 
with poorly controlled symptoms, who also experience 
hospitalization.88,89 A second study in 2007 evaluating 
cost  effectiveness  also  concluded  that  Omalizumab 
was not cost effective for most patients with severe 
asthma,  and  suggested  that  physicians  explore  all 
options before turning to Omalizumab.90
The recent 2010 Canadian Thoracic Society (CTS) 
consensus statement on the management of asthma 
discusses the use of Omalizumab in clinical   practice.45 
Omalizumab is approved by Health Canada for the 
treatment  of  moderate  to  severe  persistent  allergic 
asthma in patients greater than 12 years of age.45 Given 
the high cost, discussed above, specific criteria have 
been set forth for the use of Omalizumab. Patients 
must have difficult to control asthma, as confirmed by 
objective measures, documented allergy to aeroaller-
gens, a serum total IgE level between 30 IU/mL and 
700 IU/mL, and uncontrolled symptoms despite ther-
apy with high dose ICS and one additional controller 
medication.45 The updated GINA guidelines published 
in 2008 echo the indications for treatment set forth by 
the CTS. Given the available studies, Omalizumab 
has been shown to be safe add-on therapy.16
Anti-cytokine therapy
Tumor necrosis factor- α inhibitors were thought to be 
of benefit in the treatment of severe asthma. However, 
in  a  large,  double-blind,  placebo-controlled,  dose 
ranging trial with a monoclonal antibody to TNF-α, 
golimumab,  demonstrated  unfavorable  risk-benefit 
ratio which led to premature discontinuation of the 
trial.91 Thus, TNF-α inhibitors do not seem to be a 
favorable therapeutic option for severe asthmatics.
Bronchial thermoplasty
More  than  5  years  ago,  dog  experiments  revealed 
that bronchial thermoplasty might have therapeutic 
benefits  for  asthma  subjects  by  reducing  airway 
hyperresponsiveness.92  Bronchial  thermoplasty  is 
a  bronchoscopic  procedure  where  controlled  radio 
frequency energy is delivered to the airways in order to 
reduce the airway smooth muscle mass and attenuate 
bronchoconstriction.  This  has  now  been  tested  in 
asthmatic subjects in randomized controlled trials. The 
earlier trials performed on moderately severe and severe 
asthmatic subjects were disappointing due to the notable 
adverse effects of the treatment and the lack of any effect 
on airway hyperresponsiveness.93,94 None the less, these 
trials demonstrated that bronchial thermoplasty was 
superior to usual care with respect to asthma control and 
asthma-related quality of life, with variable effects 
on peak expiratory flow, FEV1, asthma symptoms, and 
symptom-free days. However, high potential of placebo 
effect could not be ruled out in these earlier trials.95 A well 
powered,  sham  controlled,  double-blind  multi-center 
study hence was designed (AIR2) to evaluate the safety 
and  effectiveness  of  bronchial  thermoplasty  in  adult 
patients with severe asthma who were symptomatic, 
despite the use of high-dose standard care medications.96 
AIR2 did not meet the primary endpoint of minimal 
clinically important difference in asthma-related quality 
of life questionnaire score. Procedure related respiratory 
adverse events were more common in the thermoplasty 
group and 30% were classified as moderate to severe 
grade.97 Thus, bronchial thermoplasty can not be offered 
to severe/refractory asthmatics as it has neither proven 
to be effective nor safe.
conclusions
Severe/refractory asthma is likely to represent a het-
erogeneous population; however, the specific subtypes 
have not yet been well defined. A better understanding 
of these subtypes could potentially lead to improved 
treatment  of  severe  asthmatics  stratified  by  pheno-
types. Severe asthma is a small subset of asthmatics; Management of severe asthma
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however it presents with greater morbidity and a dis-
proportionate need for health care support compared 
with less severe asthmatics. Thus, network approach to 
care and management of severe asthma is suggested.16 
In Europe, nine European   countries formed a European 
Network For Understanding Mechanisms Of Severe 
Asthma (ENFUMOSA)98 and in the United States, four 
leading university   centers are linked through the Severe 
Asthma Research   Program (SARP).99 In Canada, the 
Canadian Network of Severe Asthma (CSAN) is in the 
process of expansion and establishing consistent inves-
tigative protocols across all centers.100 The Brussels’s 
declaration demonstrates the need for change in asthma 
management and funding “real world” studies because 
of the substantial unmet clinical need which, in the 10% 
of patients with severe disease, accounts for approx. 50% 
of the health care costs.101 Continued global efforts and 
collaboration for further studies to understand severe/
refractory asthma pathobiology and optimal treatment 
strategies are mandatory.
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